Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals.
CD49d
CLL
NOTCH1
bimodal
treatment-free interval
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
23
06
2022
received:
25
04
2022
accepted:
27
06
2022
pubmed:
2
7
2022
medline:
13
10
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
This study was carried out to assess the prognostic power of low CD49d expression (≥10%) in newly diagnosed CLL patients using a previously described cohort. Eighty-five patients were included. Median age at diagnosis; 70 years (43-88); CD49d was expressed in 33/85 (38.8%); 23/33 (69.7%) at ≥30% referred to as 'HiCD49d' and 10/33 (30.3%) between 10 and 30% with a bimodal pattern on scatterplot analysis referred to as 'LoCD49d'. Eleven patients (12.9%) presented as Binet stage B, of whom 8 (72.7%) were CD49d+ (HiCD49d 7/8; LoCD49d 1/8). Seven of 81 patients (8.6%) were NOTCH1 mutated and all were CD49d+ (p ≤ .01). IgVH analysis was performed on 29 (87.8%) of the CD49d+ cases, of whom 21 (72.4%) were unmutated and 8 (27.6%) were mutated. CD38+/CD49d+ accounted for 11/20 (55%) (CD38+/HiCD49D: 9/11; CD38+/LoCD49D: 2/11). At 42 months, treatment had been initiated in 18/85 (21%) patients, of these 10/33 (30.3%) were CD49d+ versus 8/52 (15.4%) of the CD49d- group. The median treatment free interval for the CD49d+ group was 11 months (HiCD49d; 14.5 months, LoCD49d; 11 months) compared to 21.5 months for the CD49d- group. These findings suggest that the predictive value of CD49d expression is retained at expression levels down to 10%.
Identifiants
pubmed: 35776688
doi: 10.1111/ejh.13824
pmc: PMC9804520
doi:
Substances chimiques
Integrin alpha4
143198-26-9
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-446Subventions
Organisme : Unrestricted research grant from ABBVIE Inc
Informations de copyright
© 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):38-42
pubmed: 28195089
Hematology Am Soc Hematol Educ Program. 2010;2010:481-8
pubmed: 21239840
Blood. 2013 Nov 7;122(19):3317-21
pubmed: 24068493
Leukemia. 2006 Mar;20(3):523-5; author reply 528-9
pubmed: 16408095
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Oncol. 2018 Jun 27;8:229
pubmed: 29998084
Leukemia. 2018 May;32(5):1070-1080
pubmed: 29467486
J Clin Oncol. 2014 Mar 20;32(9):897-904
pubmed: 24516016
Leukemia. 1999 Feb;13(2):266-74
pubmed: 10025901
Blood. 2012 Jan 12;119(2):521-9
pubmed: 22077063
Br J Haematol. 2022 Mar;196(5):e47-e49
pubmed: 34783371
Blood. 2020 Apr 9;135(15):1244-1254
pubmed: 32006000
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Leukemia. 2018 Mar;32(3):654-662
pubmed: 28935990
Leuk Res. 2011 Jun;35(6):750-6
pubmed: 21093051
Leukemia. 2012 Jun;26(6):1301-12
pubmed: 22289918
Br J Haematol. 2008 Mar;140(5):537-46
pubmed: 18275431
Eur J Haematol. 2022 Nov;109(5):441-446
pubmed: 35776688
Blood. 2002 Aug 15;100(4):1410-6
pubmed: 12149225
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):329-337
pubmed: 29222275
Ann Hematol. 2014 Mar;93(3):361-74
pubmed: 24288111
Hematology. 2005 Feb;10(1):39-46
pubmed: 16019444
Am J Clin Pathol. 1997 Oct;108(4):378-82
pubmed: 9322589
Semin Hematol. 2014 Jul;51(3):168-76
pubmed: 25048781
Intern Med J. 2012 Feb;42(2):137-46
pubmed: 20561095
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
Haematologica. 2018 Dec;103(12):1956-1968
pubmed: 30442727
Br J Haematol. 2017 Jul;178(1):99-105
pubmed: 28386906
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713